Fibrotic response induced by angiotensin-II requires NAD(P)H oxidase-induced reactive oxygen species (ROS) in skeletal muscle cells

Biochemical and Biophysical Research Communications

Volumn 410, Issue 3, 2011, Pages 665-670

  Cabello Verrugio, Claudio ^a,b   Acuña, María José ^b   Morales, María Gabriela ^b   Becerra, Alvaro ^c   Simon, Felipe ^c   Brandan, Enrique ^b  

^a UNIVERSIDAD DEL DESARROLLO   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UNIVERSIDAD ANDRÉS BELLO   (Chile)

Author keywords

Angiotensin II; AT 1 receptor; Fibrosis; NAD(P)H oxidase; Reactive oxygen species (ROS); Skeletal muscle

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; APOCYNIN; CHELERYTHRINE; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; DIPHENYLIODONIUM SALT; FIBRONECTIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME RELEASE; MOUSE; MYOBLAST; MYOFIBROSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 79960062769     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.06.051     Document Type: Article

References (36)

1. Bataller R., Gabele E., Parsons C.J., et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 2005, 41:1046-1055.
2. Brecher P. Angiotensin II and cardiac fibrosis. Trends Cardiovasc. Med. 1996, 6:193-198.
3. Guo G., Morrissey J., McCracken R., et al. Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis. Am. J. Physiol. Renal Physiol. 2001, 280:F777-F785.
4. Seccia T.M., Belloni A.S., Kreutz R., et al. Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J. Am. Coll. Cardiol. 2003, 41:666-673.
5. Tarif N., Bakris G.L. Angiotensin II receptor blockade and progression of nondiabetic-mediated renal disease. Kidney Int. Suppl. 1997, 63:S67-S70.
6. Lakshmanan A.P., Watanabe K., Thandavarayan R.A., et al. Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-gamma agonist action. Free Radic. Res. 2011, 45:575-584.
7. Briones A.M., Rodriguez-Criado N., Hernanz R., et al. Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension 2009, 54:142-149.
8. Lassegue B., Clempus R.E. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285:R277-R297.
9. Babior B.M. The activity of leukocyte NADPH oxidase: regulation by p47PHOX cysteine and serine residues. Antioxid. Redox Signal. 2002, 4:35-38.
10. Doerries C., Grote K., Hilfiker-Kleiner D., et al. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ. Res. 2007, 100:894-903.
11. Block K., Eid A., Griendling K.K., et al. Nox4 NAD(P)H oxidase mediates Src-dependent tyrosine phosphorylation of PDK-1 in response to angiotensin II: role in mesangial cell hypertrophy and fibronectin expression. J. Biol. Chem. 2008, 283:24061-24076.
12. Hanna I.R., Taniyama Y., Szocs K., et al. NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling. Antioxid. Redox Signal. 2002, 4:899-914.
13. Hannken T., Schroeder R., Stahl R.A., et al. Angiotensin II-mediated expression of p27Kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. Kidney Int. 1998, 54:1923-1933.
14. Mezzano V., Cabrera D., Vial C., et al. Constitutively activated dystrophic muscle fibroblasts show a paradoxical response to TGF-beta and CTGF/CCN2. J. Cell. Commun. Signal. 2007, 1:205-217.
15. Fadic R., Mezzano V., Alvarez K., et al. Increase in decorin and biglycan in Duchenne Muscular Dystrophy: role of fibroblasts as cell source of these proteoglycans in the disease. J. Cell. Mol. Med. 2006, 10:758-769.
16. Vial C., Zuniga L.M., Cabello-Verrugio C., et al. Skeletal muscle cells express the profibrotic cytokine connective tissue growth factor (CTGF/CCN2) which induces their dedifferentiation. J. Cell. Physiol. 2008, 215:410-421.
17. Cabello-Verrugio C., Cordova G., Vial C., et al. Connective tissue growth factor induction by lysophosphatidic acid requires transactivation of transforming growth factor type beta receptors and the JNK pathway. Cell. Signal. 2011, 23:449-457.
18. Shkryl V.M., Martins A.S., Ullrich N.D., et al. Reciprocal amplification of ROS and Ca(2+) signals in stressed mdx dystrophic skeletal muscle fibers. Pflugers Arch. 2009, 458:915-928.
19. Whitehead N.P., Yeung E.W., Froehner S.C., et al. Skeletal muscle NADPH oxidase is increased and triggers stretch-induced damage in the mdx mouse. PLoS One 2010, 5:e15354.
20. Cabello-Verrugio C., Brandan E. A novel modulatory mechanism of transforming growth factor-beta signaling through decorin and LRP-1. J. Biol. Chem. 2007, 282:18842-18850.
21. Riquelme C., Larrain J., Schonherr E., et al. Antisense inhibition of decorin expression in myoblasts decreases cell responsiveness to transforming growth factor beta and accelerates skeletal muscle differentiation. J. Biol. Chem. 2001, 276:3589-3596.
22. Caceres S., Cuellar C., Casar J.C., et al. Synthesis of proteoglycans is augmented in dystrophic mdx mouse skeletal muscle. Eur. J. Cell Biol. 2000, 79:173-181.
23. Alvarez K., Fadic R., Brandan E. Augmented synthesis and differential localization of heparan sulfate proteoglycans in Duchenne muscular dystrophy. J. Cell. Biochem. 2002, 85:703-713.
24. Sun G., Haginoya K., Dai H., et al. Intramuscular renin-angiotensin system is activated in human muscular dystrophy. J. Neurol. Sci. 2009, 280:40-48.
25. Cohn R.D., van Erp C., Habashi J.P., et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat. Med. 2007, 13:204-210.
26. Whitehead N.P., Pham C., Gervasio O.L., et al. N-Acetylcysteine ameliorates skeletal muscle pathophysiology in mdx mice. J. Physiol. 2008, 586:2003-2014.
27. Austin L., de Niese M., McGregor A., et al. Potential oxyradical damage and energy status in individual muscle fibres from degenerating muscle diseases. Neuromuscul. Disord. 1992, 2:27-33.
28. Yan H.D., Li X.Z., Xie J.M., et al. Effects of advanced glycation end products on renal fibrosis, oxidative stress in cultured NRK-49F cells. Chin. Med. J. (Engl.) 2007, 120:787-793.
29. Wang M., Zhang J., Walker S.J., et al. Involvement of NADPH oxidase in age-associated cardiacremodeling. J. Mol. Cell. Cardiol. 2010, 48:765-772.
30. Javesghani D., Magder S.A., Barreiro E., et al. Molecular characterization of a superoxide-generating NAD(P)H oxidase in the ventilatory muscles. Am. J. Respir. Crit. Care Med. 2002, 165:412-418.
31. Cheng G., Cao Z., Xu X., et al. Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5. Gene 2001, 269:131-140.
32. Hidalgo C., Sanchez G., Barrientos G., et al. A transverse tubule NADPH oxidase activity stimulates calcium release from isolated triads via ryanodine receptor type 1 S-glutathionylation. J. Biol. Chem. 2006, 281:26473-26482.
33. Espinosa A., Leiva A., Pena M., et al. Myotube depolarization generates reactive oxygen species through NAD(P)H oxidase; ROS-elicited Ca2+ stimulates ERK, CREB, early genes. J. Cell. Physiol. 2006, 209:379-388.
34. Babior B.M. NADPH oxidase. Curr. Opin. Immunol. 2004, 16:42-47.
35. Lopes L.R., Hoyal C.R., Knaus U.G., et al. Activation of the leukocyte NADPH oxidase by protein kinase C in a partially recombinant cell-free system. J. Biol. Chem. 1999, 274:15533-15537.
36. Hoyal C.R., Gutierrez A., Young B.M., et al. Modulation of p47PHOX activity by site-specific phosphorylation: Akt-dependent activation of the NADPH oxidase. Proc. Natl. Acad. Sci. USA 2003, 100:5130-5135.